Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Programme discontinued trial records

3 records with the status programme discontinued.

Showing 0 records on this page

Records

3 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
DANU-PH2B-OBESITYDanuglipronPhase 2bProgramme discontinuedRandomised, double-blind, placebo-controlled6052023Not rated
DANU-PH2B-T2DDanuglipronPhase 2bProgramme discontinuedRandomised, double-blind, placebo-controlled4112023Not rated
AOD-PH2B-OBESITYAOD-9604Phase 2bProgramme discontinuedRandomised, double-blind, placebo-controlled5362007Not rated
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.